12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Natpara regulatory update

NPS delayed its planned submission of a BLA to FDA for hypoparathyroidism product Natpara to mid-2013. The company had planned to submit it by year end. NPS said it...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >